Mehmet Boyraz
Overview
Explore the profile of Mehmet Boyraz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
206
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buyukyilmaz G, Cavdarli B, Koca S, Toksoy Adiguzel K, Topaloglu O, Aydin C, et al.
J Clin Res Pediatr Endocrinol
. 2024 Dec;
PMID: 39713907
Objective: Resistance to thyroid hormone beta (RTHβ) is a rare disorder characterized by a fairly heterogeneous clinical presentation due to varying degrees of tissue response to thyroid hormone. The study...
2.
Turhan B, Buyukyilmaz G, Boyraz M
J Pediatr Endocrinol Metab
. 2024 Dec;
38(2):187-190.
PMID: 39710518
Objectives: Hypothalamic hamartoma (HH) is a rare condition that causes epilepsy and central precocious puberty (CPP) at an early age. In this report, we describe a child with CPP secondary...
3.
Ozdemir Sahan Y, Buyukyilmaz G, Dogan O, Boyraz M, Cetin I, Ece I
J Clin Res Pediatr Endocrinol
. 2024 Nov;
PMID: 39564966
Background And Aim: Children with type 1 diabetes mellitus are susceptible to arrhythmias and sudden cardiac death. In this study, we aimed to explore the arrhythmia risk among children with...
4.
Buyukyilmaz G, Koca S, Turhan B, Toksoy Adiguzel K, Goren R, Uzdogan A, et al.
J Pediatr Endocrinol Metab
. 2024 May;
37(7):622-629.
PMID: 38800840
Objectives: Alkaline phosphatase (ALP) can be increased in a benign condition known as benign-transient hyperphosphatasemia (BTH). We aimed to evaluate the demographic, and clinical characteristics of infants and children with...
5.
Kilinc Ugurlu A, Bitkay A, Gurbuz F, Karakus E, Bayram Ilikan G, Damar C, et al.
J Clin Res Pediatr Endocrinol
. 2024 Jan;
16(2):160-167.
PMID: 38238968
Objective: The aim was to assess postoperative outcomes in pediatric thyroid nodules with atypia of undetermined significance (AUS/FLUS) or suspicious for a follicular neoplasm (SFN) and their respective the European-Thyroid...
6.
Kilinc Ugurlu A, Ozdemir Gokce A, Cakir Gundogan S, Eksioglu A, Boyraz M
Front Endocrinol (Lausanne)
. 2024 Jan;
14:1316333.
PMID: 38229738
Purpose: The aim of this study was to investigate the frequency and distribution of intracranial pathologies in female patients between 8 and 9 years of age who were diagnosed with...
7.
Buyukyilmaz G, Toksoy Adiguzel K, Aksoy O, Kasapkara C, Urel Demir G, Demir E, et al.
Turk J Pediatr
. 2024 Jan;
65(6):1025-1032.
PMID: 38204317
Background: Sphingosine phosphate lyase insufficiency syndrome (SPLIS) caused by inactivating mutations in the human SGPL1 gene results in congenital nephrotic syndrome, adrenal insufficiency, ichthyosis, immunodeficiency, and a wide range of...
8.
Buyukyilmaz G, Koca S, Toksoy Adiguzel K, Gurbuz F, Boyraz M
J Pediatr Endocrinol Metab
. 2023 Sep;
36(11):1044-1051.
PMID: 37735929
Objectives: Gonadotropin-releasing hormone agonist (GnRHa) has been used for central precocious puberty (CPP) or early and fast puberty. It was aimed to assess changes in body mass index (BMI), polycystic...
9.
Buyukyilmaz G, Erozan Cavdarli B, Toksoy Adiguzel K, Adiguzel M, Kasapkara C, Gurbuz F, et al.
J Clin Res Pediatr Endocrinol
. 2023 Mar;
PMID: 36974356
4H syndrome is a rare progressive hypomyelinating leukodystrophy. Hypomyelination, hypodontia, and hypogonadotropic hypogonadism are the 3 classic features of 4H syndrome. Biallelic pathogenic variants in POLR3A, POLR3B, POLR1C, and POLR3K...
10.
Evaluation of Hypersensitivity Reactions with Leuprolide Acetate and Triptorelin Acetate in Children
Metbulut A, Toksoy Adiguzel K, Islamoglu C, Boyraz M, Misirlioglu E
Indian J Endocrinol Metab
. 2022 Mar;
25(6):527-531.
PMID: 35355908
Introduction: Gonadotropin releasing hormone analogues (GnRHa) are commonly used to treat central precocious puberty (CPP). Generally, they are well-tolerated; however adverse reactions have been reported. Local adverse events occur in...